Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients.

Publication date: Dec 04, 2023

The Patient Reported Outcome for Fighting FInancial Toxicity (PROFFIT) questionnaire was developed to measure financial toxicity (FT) and identify its determinants. The aim of the present study was to confirm its validity in a prospective cohort of patients receiving anticancer treatment. From March 2021 to July 2022, 221 patients were enrolled at 10 Italian centres. Selected items of the EORTC-QLQ-C30 questionnaire represented the anchors, specifically, question 28 (Q-28) on financial difficulties, and questions 29-30 measuring global health status/quality of life (HR-QOL). The study had 80% power to detect a 0. 20 correlation coefficient (r) between anchors and PROFFIT-score (items 1-7, range 0-100, 100 indicating maximum FT) with bilateral alpha 0. 05 and 80% power. Confirmatory factor analysis was conducted. FT determinants (items 8-16) were described. Median age of patients was 65 years, 116 (52. 5%) were females, 96 (43. 4%) had low education level. Confirmatory factor analysis confirmed goodness of fit of the PROFFIT-score. Significant partial correlation of PROFFIT-score was found with Q-28 (r = 0. 51) and HR-QOL (r = -0. 23). Mean (SD) PROFFIT-score at baseline was 36. 5 (24. 9); it was statistically significantly higher for patients living in South Italy, those with lower education level, those who were freelancer/unemployed at diagnosis and those who reported significant economic impact from the COVID-19 pandemic. Mean (SD) scores of determinants ranged from 17. 6 (27. 1) for item 14 (support from medical staff) to 49. 0 (36. 3) for item 10 (expenses for medicines or supplements). PROFFIT-score significantly increased with worsening response to determinants. External validation of PROFFIT-score in an independent sample of patients was successful. The instrument is now being used in clinical studies.

Open Access PDF

Concepts Keywords
Females financial toxicity
Italian health economics
July patient reported outcomes
Pandemic PROFFIT
quality of life


Type Source Name
disease MESH cancer
drug DRUGBANK Dihydrotachysterol
disease IDO quality
disease MESH education level
disease MESH COVID-19 pandemic
drug DRUGBANK Etoperidone

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *